GlassScriptPhysician profile
Erin E Kempe
NPI 1790005692
$2,420.52
in general payments reported to CMS, 2019-2025
22 companies · $645 in 2025
The $645 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $79.59 · 2021: $225 · 2022: $100 · 2023: $608 · 2024: $572 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753 · Education: $71.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.48 |
| Education | $71.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $503.71 | 2020-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $335.83 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $297.88 | 2023-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $219.99 | 2020-2025 | Hyqvia, Cuvitru |
| Csl Behring | $184.45 | 2022-2025 | Hizentra |
| Pfizer INC. | $175.48 | 2019-2025 | |
| Genzyme Corporation | $95.35 | 2023-2025 | |
| Derma Sciences, INC. | $95.27 | 2019 | |
| Optinose US, INC. | $95.07 | 2019-2021 | |
| Lilly USA, LLC | $69.38 | 2025 | Ebglyss |
| Incyte Corporation | $57.50 | 2023-2025 | Opzelura |
| Genentech USA, INC. | $42.44 | 2019-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $41.03 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $31.72 | 2023-2024 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $31.66 | 2025 | Neffy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $26.59 | 2024 | Auvi-Q |
| Abbvie INC. | $25.25 | 2022 | |
| Inspire Medical Systems, INC. | $23.45 | 2024 | Inspire |
| Amgen INC. | $19.79 | 2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $19.37 | 2025 | |
| Hospira, INC. | $16.31 | 2024 | |
| Grifols USA, LLC | $13.00 | 2023 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Kempe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.